Educational Activities Archives

This episode of the Stigma and Substance Use podcast, explores the “contagious” nature of stigma in substance use disorders (SUDs), revealing how shame and discrimination spread beyond the 45-50 million Americans with SUDs to affect an estimated 45-300 million family members. While stigma’s impact on individuals with SUDs is well-documented, this conversation spotlights how families become “stigmatized by association,” driving them “underground” and leading to isolation, delayed help-seeking, compromised mental health, strained relationships, and poorer recovery outcomes for the entire family system.

This session provides a comprehensive overview of the interprofessional team approach to substance use disorder (SUD) treatment. It emphasizes the importance of collaboration among a variety of professionals to address the complex needs of individuals in recovery. This case-based discussion will define interprofessional collaboration, explore the unique contributions of peer specialists, and discuss available evidence-based non-pharmacologic treatments. Participants will also learn about holistic approaches to recovery, which address the mind, body, and spirit. The session will provide practical strategies and resources for building and sustaining effective interprofessional teams, promoting optimal outcomes for individuals with SUD.

In this episode of the Stigma and Substance Use Podcast, we dive into why language in client and patient records matters—and how it can shape care experiences. We explore practical ways to use non-stigmatizing language in health records and discuss the role of electronic health record (EHR) in shaping documentation. Who designs these systems, and how can they be improved? We also examine real-world case scenarios where stigmatizing notes have had lasting impacts on individuals. Whether you’re a provider, policymaker, or advocate, this episode offers insight into making health records more respectful, equitable, and aligned with patient-centered care.

Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.